Therapy Areas: Respiratory
Moderna to Build mRNA Facility in Africa to Manufacture up to 500m Doses Per Year
7 October 2021 - - US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) will build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500m doses of vaccines each year at the 50 µg dose level, the company said.

The company anticipates investing up to USD 500m in this new facility which is expected to include drug substance manufacturing with the opportunity for fill/finish and packaging capabilities at the site. The company expects to begin a process for country and site selection soon.

Moderna and its partners have ramped up capacity worldwide and have supplied more than 500 m doses of Moderna's COVID-19 vaccine to date.

As recently announced, there are several efforts to continue increasing capacity at a significant pace.

This announcement is a new investment aimed at adding a manufacturing site in Africa to Moderna's expanding global network.

Moderna's pipeline includes 20 vaccine candidates in its prophylactic vaccines modality including vaccines against respiratory viruses, vaccines against latent viruses and vaccines against threats to global public health.


Related Headlines